End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience

To evaluate the previously reported excess of thromboembolic events during the 30 days after the end of study (EOS) visit when participants transitioned from blinded therapy to open-label vitamin K antagonist. At the EOS visit, open-label vitamin K antagonist was recommended, and the international n...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation Cardiovascular quality and outcomes 2013-07, Vol.6 (4), p.470-478
Hauptverfasser:	Mahaffey, Kenneth W, Hellkamp, Anne S, Patel, Manesh R, Hannan, Karen L, Schwabe, Kimberly, Nessel, Christopher C, Berkowitz, Scott D, Halperin, Jonathan L, Hankey, Graeme J, Becker, Richard C, Piccini, Jonathan P, Breithardt, Günter, Hacke, Werner, Singer, Daniel E, Califf, Robert M, Fox, Keith A A
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Anticoagulants - administration & dosage Anticoagulants - adverse effects Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Blood Coagulation - drug effects Clinical Protocols Continuity of Patient Care Double-Blind Method Drug Administration Schedule Drug Substitution Embolism - etiology Embolism - prevention & control Factor Xa - metabolism Factor Xa Inhibitors Female Humans International Normalized Ratio Male Middle Aged Morpholines - administration & dosage Morpholines - adverse effects Proportional Hazards Models Research Design Risk Factors Rivaroxaban Stroke - etiology Stroke - prevention & control Thiophenes - administration & dosage Thiophenes - adverse effects Time Factors Treatment Outcome Vitamin K - antagonists & inhibitors Vitamin K - blood Warfarin - administration & dosage Warfarin - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!